Navigation Links
Dyadic International Raises $3 Million in Private Placement of Convertible Notes
Date:8/24/2010

JUPITER, Fla., Aug. 24 /PRNewswire-FirstCall/ -- Dyadic International, Inc. ("Dyadic") (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that it has completed a private placement of $3,000,000 in convertible subordinated secured promissory notes (the "Notes") with two investors.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO)

The Notes will pay interest quarterly at a rate of 8% per annum. The Notes will be convertible, at the holder's option after January 1, 2011, into shares of Dyadic common stock at a conversion price of $1.82 which represents 120% of the average closing price for the 30-day period preceding the closing date. The Notes mature on January 1, 2013.

Dyadic expects to use proceeds from this offering for working capital including continued investments in research and development and new product introductions, and general corporate purposes.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This financing provides Dyadic with a timely source of capital on terms that are substantially less dilutive for Dyadic's stockholders than other capital raising alternatives. The proceeds of this offering strengthen Dyadic's balance sheet and improves our working capital which puts Dyadic in a better position to negotiate additional licensing arrangements and strategic collaborations on the best possible terms for the benefit of Dyadic and its stockholders."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
2. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
3. Dyadic International Engages The Abraham Group as Strategic Advisor
4. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
5. Dyadic International Strengthens Management Team
6. Dyadic International Extends Collaboration With The Scripps Research Institute
7. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
8. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
9. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
10. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
11. FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Luxembourg (PRWEB) , ... April 27, 2017 , ... Mitotech ... study in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic ... efficacy of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... and a name change to Fluence Analytics. , Fluence Analytics provides ... polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented technologies ...
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... and North America this May on the following dates: , ... H. Taylor, Chairman of the Learning and Performance Institute will be the ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):